Biognosys continuously realizes an increasing depth of analysis in all key biofluid sample types. We can now quantify and visualize up to 5,000 of the most relevant proteins in CSF and urine samples. Our mass spectrometry-based proteomics solutions offer unlimited possibilities for unbiased discovery to uncover true biology.

Join us at booth 31 or at our presentation, “Quantitative Dissection of Healthy Aging and Cognitive Decline Using Proteoform Signatures from Paired CSF and Plasma,” which will take place on March 18th in the session from 2:45 - 4:45 pm. We will discuss the results of our recent study in collaboration with Prof. Abhay Moghekar from Johns Hopkins University School of Medicine, Department of Neurology.

Webinar alert! Join us at Nature Research Custom Media on Wednesday, March 16th at 4 pm CET to learn about: 

- How to perform global analyses of altered protein structures in situ and what we can discover from these analyses 

- How we can better connect systems biology and mechanistic biological analyses 

- Approaches to generating hypotheses on biological mechanisms and drug targets at high throughput

Webinar alert! Join us on Science on Wednesday, March 30th at 4 pm CET to learn about:

- Novel insights into CD40 and its role in activating the immune system against cancer

- The application of a multi-omics biomarker approach to monitoring pharmacodynamic markers

- Mass spectrometry-based plasma proteomics 

- Integration of single-cell technologies with population-level omics, such as proteomics

Our latest blog article explores the emerging field of immunopeptidomics: studying the repertoire of peptide fragments presented to the immune system by healthy, infected, or cancerous cells. This information provides powerful insights into more effective, personalized immunotherapies for cancer and autoimmune diseases, as well as novel treatments and vaccines for infectious diseases.